Review



103633 protac era degrader 2 medchemexpress cat  (MedChemExpress)


Bioz Verified Symbol MedChemExpress is a verified supplier
Bioz Manufacturer Symbol MedChemExpress manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 93
      Buy from Supplier

    Structured Review

    MedChemExpress 103633 protac era degrader 2 medchemexpress cat
    103633 Protac Era Degrader 2 Medchemexpress Cat, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 2 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/103633 protac era degrader 2 medchemexpress cat/product/MedChemExpress
    Average 93 stars, based on 2 article reviews
    103633 protac era degrader 2 medchemexpress cat - by Bioz Stars, 2026-02
    93/100 stars

    Images



    Similar Products

    103633 protac era degrader 2 medchemexpress cat  (MedChemExpress)
    93
    MedChemExpress 103633 protac era degrader 2 medchemexpress cat
    103633 Protac Era Degrader 2 Medchemexpress Cat, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/103633 protac era degrader 2 medchemexpress cat/product/MedChemExpress
    Average 93 stars, based on 1 article reviews
    103633 protac era degrader 2 medchemexpress cat - by Bioz Stars, 2026-02
    93/100 stars
    		  Buy from Supplier
    protac bet degrader-1  (MedChemExpress)
    93
    MedChemExpress protac bet degrader-1
    Protac Bet Degrader 1, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/protac bet degrader-1/product/MedChemExpress
    Average 93 stars, based on 1 article reviews
    protac bet degrader-1 - by Bioz Stars, 2026-02
    93/100 stars
    		  Buy from Supplier
    protac bet degrader 1  (MedChemExpress)
    93
    MedChemExpress protac bet degrader 1
    Chemical structures of tested compounds. The compounds tested included pan-BRD PROTAC dBET1, PROTAC BET <t>Degrader-1,</t> and PROTAC BET Degrader-2; the pan-BRD ligands (+)-JQ1 and HJB97; the cereblon ligands thalidomide and lenalidomide; the BRD/BD2 selective ligand RVX-208; and the VHL ligand VH032.
    Protac Bet Degrader 1, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/protac bet degrader 1/product/MedChemExpress
    Average 93 stars, based on 1 article reviews
    protac bet degrader 1 - by Bioz Stars, 2026-02
    93/100 stars
    		  Buy from Supplier

    Image Search Results


    Chemical structures of tested compounds. The compounds tested included pan-BRD PROTAC dBET1, PROTAC BET Degrader-1, and PROTAC BET Degrader-2; the pan-BRD ligands (+)-JQ1 and HJB97; the cereblon ligands thalidomide and lenalidomide; the BRD/BD2 selective ligand RVX-208; and the VHL ligand VH032.

    Journal: ACS Pharmacology & Translational Science

    Article Title: General Stepwise Approach to Optimize a TR-FRET Assay for Characterizing the BRD/PROTAC/CRBN Ternary Complex

    doi: 10.1021/acsptsci.1c00032

    Figure Lengend Snippet: Chemical structures of tested compounds. The compounds tested included pan-BRD PROTAC dBET1, PROTAC BET Degrader-1, and PROTAC BET Degrader-2; the pan-BRD ligands (+)-JQ1 and HJB97; the cereblon ligands thalidomide and lenalidomide; the BRD/BD2 selective ligand RVX-208; and the VHL ligand VH032.

    Article Snippet: We purchased dBET1, PROTAC BET Degrader-1, PROTAC BET Degrader-2, HJB97, thalidomide, and lenalidomide from MedChemExpress USA (Monmouth Junction, NJ).

    Techniques:

    TR-FRET dose–response curves of PROTAC ternary complex formation. The compounds tested include dBET1, PROTAC BET Degrader-1, PROATC BET Degrader-2, (+)-JQ1, HJB97, thalidomide, and lenalidomide. The assays were performed under condition 5 with a 180 min incubation with Tb-anti-GST (2 nM), GST-BRD2(BD1) (2 nM), His-CRBN(DDB1) (8 nM), and AF488-anti-His (4 nM). (a) Relative TR-FRET signals in RTU (10 000 × 520 nm/490 nm). (b) Normalized TR-FRET signals as fold change to DMSO.

    Journal: ACS Pharmacology & Translational Science

    Article Title: General Stepwise Approach to Optimize a TR-FRET Assay for Characterizing the BRD/PROTAC/CRBN Ternary Complex

    doi: 10.1021/acsptsci.1c00032

    Figure Lengend Snippet: TR-FRET dose–response curves of PROTAC ternary complex formation. The compounds tested include dBET1, PROTAC BET Degrader-1, PROATC BET Degrader-2, (+)-JQ1, HJB97, thalidomide, and lenalidomide. The assays were performed under condition 5 with a 180 min incubation with Tb-anti-GST (2 nM), GST-BRD2(BD1) (2 nM), His-CRBN(DDB1) (8 nM), and AF488-anti-His (4 nM). (a) Relative TR-FRET signals in RTU (10 000 × 520 nm/490 nm). (b) Normalized TR-FRET signals as fold change to DMSO.

    Article Snippet: We purchased dBET1, PROTAC BET Degrader-1, PROTAC BET Degrader-2, HJB97, thalidomide, and lenalidomide from MedChemExpress USA (Monmouth Junction, NJ).

    Techniques: Incubation

    Dose–response curves of competing compounds in the TR-FRET GST-BRD2(BD1)/PROTAC BET Degrader 1/His-CRBN(DDB1) ternary complex formation assay. The compounds tested included (+)-JQ1, HJB97, thalidomide, lenalidomide, RVX-208, and VH032. PROTAC BET Degrader 1 (4.1 nM) was used under condition 5 with Tb-anti-GST (2 nM), GST-BRD2(BD1) (2 nM), His-CRBN(DDB1) (8 nM), and AF488-anti-His (4 nM) with a 180 min incubation.

    Journal: ACS Pharmacology & Translational Science

    Article Title: General Stepwise Approach to Optimize a TR-FRET Assay for Characterizing the BRD/PROTAC/CRBN Ternary Complex

    doi: 10.1021/acsptsci.1c00032

    Figure Lengend Snippet: Dose–response curves of competing compounds in the TR-FRET GST-BRD2(BD1)/PROTAC BET Degrader 1/His-CRBN(DDB1) ternary complex formation assay. The compounds tested included (+)-JQ1, HJB97, thalidomide, lenalidomide, RVX-208, and VH032. PROTAC BET Degrader 1 (4.1 nM) was used under condition 5 with Tb-anti-GST (2 nM), GST-BRD2(BD1) (2 nM), His-CRBN(DDB1) (8 nM), and AF488-anti-His (4 nM) with a 180 min incubation.

    Article Snippet: We purchased dBET1, PROTAC BET Degrader-1, PROTAC BET Degrader-2, HJB97, thalidomide, and lenalidomide from MedChemExpress USA (Monmouth Junction, NJ).

    Techniques: Tube Formation Assay, Incubation

    DMSO tolerance test of the PROTAC BET Degrader-1 TR-FRET ternary complex formation assay. Tb-anti-GST (2 nM), GST-BRD2(BD1) (2 nM), His-CRBN(DDB1) (8 nM), and AF488-anti-His (4 nM) were used with a 180 min incubation. (a) Relative TR-FRET signals (10 000 × 520 nm/490 nm, RTU). (b) Normalized TR-FRET signals (as fold change to DMSO). TR-FRET signals from the DMSO control are displayed to the left of the curves.

    Journal: ACS Pharmacology & Translational Science

    Article Title: General Stepwise Approach to Optimize a TR-FRET Assay for Characterizing the BRD/PROTAC/CRBN Ternary Complex

    doi: 10.1021/acsptsci.1c00032

    Figure Lengend Snippet: DMSO tolerance test of the PROTAC BET Degrader-1 TR-FRET ternary complex formation assay. Tb-anti-GST (2 nM), GST-BRD2(BD1) (2 nM), His-CRBN(DDB1) (8 nM), and AF488-anti-His (4 nM) were used with a 180 min incubation. (a) Relative TR-FRET signals (10 000 × 520 nm/490 nm, RTU). (b) Normalized TR-FRET signals (as fold change to DMSO). TR-FRET signals from the DMSO control are displayed to the left of the curves.

    Article Snippet: We purchased dBET1, PROTAC BET Degrader-1, PROTAC BET Degrader-2, HJB97, thalidomide, and lenalidomide from MedChemExpress USA (Monmouth Junction, NJ).

    Techniques: Tube Formation Assay, Incubation

    Comparison of PROTAC BET Degrader-1, PROTAC BET Degrader-2, and dBET1 for their Previously Reported IC 50 Values and TR-FRET Maximal PROTAC Efficacy Concentrations

    Journal: ACS Pharmacology & Translational Science

    Article Title: General Stepwise Approach to Optimize a TR-FRET Assay for Characterizing the BRD/PROTAC/CRBN Ternary Complex

    doi: 10.1021/acsptsci.1c00032

    Figure Lengend Snippet: Comparison of PROTAC BET Degrader-1, PROTAC BET Degrader-2, and dBET1 for their Previously Reported IC 50 Values and TR-FRET Maximal PROTAC Efficacy Concentrations

    Article Snippet: We purchased dBET1, PROTAC BET Degrader-1, PROTAC BET Degrader-2, HJB97, thalidomide, and lenalidomide from MedChemExpress USA (Monmouth Junction, NJ).

    Techniques: Comparison, Inhibition, Concentration Assay

    Effect of DMSO Concentration on the Peak Relative TR-FRET Signal and the Corresponding Maximal PROTAC Efficacy Concentration for PROTAC BET Degrader-1 in the TR-FRET Complex Formation Assay

    Journal: ACS Pharmacology & Translational Science

    Article Title: General Stepwise Approach to Optimize a TR-FRET Assay for Characterizing the BRD/PROTAC/CRBN Ternary Complex

    doi: 10.1021/acsptsci.1c00032

    Figure Lengend Snippet: Effect of DMSO Concentration on the Peak Relative TR-FRET Signal and the Corresponding Maximal PROTAC Efficacy Concentration for PROTAC BET Degrader-1 in the TR-FRET Complex Formation Assay

    Article Snippet: We purchased dBET1, PROTAC BET Degrader-1, PROTAC BET Degrader-2, HJB97, thalidomide, and lenalidomide from MedChemExpress USA (Monmouth Junction, NJ).

    Techniques: Concentration Assay